Targeting the c-kit receptor in the treatment of acute myelogenous leukemia

被引：11
作者：
Advani A.S. [1 ]
机构：
[1] Cleveland Clinic Foundation, Cleveland, OH 44195
来源：
Current Hematologic Malignancy Reports | 2006年 / 1卷 / 2期
关键词：
Acute Myeloid Leukemia; Imatinib; Acute Myelogenous Leukemia; Stem Cell Factor; Imatinib Mesylate;
D O I：
10.1007/s11899-006-0020-9
中图分类号：
学科分类号：
摘要：
Acute myelogenous leukemia (AML) is a difficult disease to treat. Novel treatment strategies, including molecular targeted therapy, are being explored. The c-kit receptor represents a potential therapeutic target for AML. The receptor is expressed on more than 10% of blasts in 64% of patients with de novo AML and 95% of those with relapsed AML. It mediates proliferation and anti-apoptotic effects in AML. This review discusses the biology of c-kit in normal and malignant hematopoiesis and the recent clinical trials targeting c-kit in AML. Copyright © 2006 by Current Science Inc.
引用
收藏
页码：101 / 107
页数：6
相关论文
共 57 条
[1]  
Miller K., Daoust P., Clinical manifestations of acute myeloid leukemia, Hematology: Basic Principles and Practice, Edn 3, pp. 2017-2018, (2000)
[2]  
Hans C.P., Finn W.G., Singleton T.P., Et al., Usefulness of anti-CD117 in the flow cytometric analysis of acute leukemia, Am J Clin Pathol, 117, pp. 301-305, (2002)
[3]  
Del Poeta G., Venditti A., Maurillo L., Et al., The amount of c-kit receptor tyrosine kinase predicts outcome in acute myelogenous leukemia, Blood (ASH Annual Meeting Abstracts), 98, (2001)
[4]  
Tajima F., Kawatani T., Ishiga K., Et al., Serum soluble c-kit receptor and expression of c-kit protein and mRNA in acute myeloid leukemia, Eur J Haematol, 60, pp. 289-296, (1998)
[5]  
Yarden Y., Kuang W.I., Yang-Feng T., Et al., Human proto-oncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand, Embo J, 6, pp. 3341-3351, (1987)
[6]  
Zsebo K.M., Williams D.A., Geissler E.N., Et al., Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor, Cell, 63, pp. 213-224, (1990)
[7]  
Lev S., Givol D., Yarden Y., A specific combination of substrates is involved in signal transduction by the kit-encoded receptor, Embo J, 10, pp. 647-654, (1991)
[8]  
Piao X., Curtis J.E., Minkin S., Et al., Expression of the Kit and KitA receptor isoforms in human acute myelogenous leukemia, Blood, 83, pp. 476-481, (1994)
[9]  
Koch C.A., Anderson D., Moran M.F., Et al., SH2 and SH3 domains: Elements that control interactions of cytoplasmic signaling proteins, Science, 252, pp. 668-674, (1991)
[10]  
Kindler T., Breitenbuecher F., Marx A., Et al., Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML, Blood, 101, pp. 2960-2962, (2003)
123456